GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit

E-ISSN： 1463-1326|17|7|622-629

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.7, 2015-07, pp. : 622-629

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Multiple‐Ascending‐Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK‐875, in Subjects With Type 2 Diabetes

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 1, 2012-07 ,pp. : 29-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

TNF, TNF inducers, and TNFR2 agonists: A new path to type 1 diabetes treatment

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Perceptions and experiences of taking oral medications for the treatment of Type 2 diabetes mellitus: a systematic review and meta‐synthesis of qualitative studies

DIABETIC MEDICINE, Vol. 33, Iss. 10, 2016-10 ,pp. : 1330-1338

John Wiley & Sons Inc

Access to resources Recommend Favorite

Xultophy: combination therapy for the treatment of type 2 diabetes

PRESCRIBER, Vol. 26, Iss. 17, 2015-09 ,pp. : 32-34

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tailoring treatment to risk in type 2 diabetes

By Graffy Jonathan

British Journal of General Practice, Vol. 60, Iss. 572, 2010-03 ,pp. : 158-160

Royal College of General Practitioners

Access to resources Recommend Favorite